Signify (F.K.A. Remedy Bpci Partners, LLC)
Remedy provides value-based care solutions within the health care sector
Based in CT
🤖
AI Overview
With $1.1M in lobbying spend across 15 quarterly filings, Signify (F.K.A. Remedy Bpci Partners, LLC) is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2019 to 2022.
$1.1M
Total Spend
4
Years Active
1
Firms Hired
9
Lobbyists Deployed
3
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $130K |
| 2020 | $320K |
| 2021 | $320K |
| 2022 | $320K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Budget/Appropriations
- •CMMI,
- •Bundled payments
- •Bundled Payment for Care Improvement demo
- •Value based care
- •Bundled Payment for Care Improvement demo
- •Value based care
- •CMMI
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Wholesome Wave National Produce Prescription Collaborative
$655K total spend
Shire Pharmaceuticals LLC Formerly Known as Shire Regenerative Medicine
$220K total spend
Connecticut Children's Medical Center
$100K total spend
Wholesome Wave, INC.
$40K total spend
Signify (F.K.A. Remedy Bpci Partners, LLC)
$0 total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.